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Trp/Tyr ﬂuorescenceBP100 is a short cationic antimicrobial peptide with a mechanism of action dependent on peptide–lipid interac-
tions andmicrobial surface charge neutralization. Although active against Gram-negative bacteria, BP100 is inac-
tive against Gram-positive bacteria. In this study we report two newly designed BP100 analogues, RW-BP100
and R-BP100 that have the Tyr residue replaced with a Trp and/or the Lys residues replaced with an Arg. The
new analogues in addition to being active against Gram-negative bacteria, possess activity against all tested
Gram-positive bacteria.Mechanistic studies using atomic forcemicroscopy, surface plasmon resonance and ﬂuo-
rescence methodologies reveal that the antibacterial efﬁciency follows the afﬁnity for bacterial membrane. The
studies suggest that the activity of BP100 and its analogues against Gram-negative bacteria is mainly driven by
electrostatic interactions with the lipopolysaccharide layer and is followed by binding to and disruption of the
inner membrane, whereas activity against Gram-positive bacteria, in addition to electrostatic attraction to the
exposed lipoteichoic acids, requires an ability to more deeply insert in the membrane environment, which is
favoured with Arg residues and is facilitated in the presence of a Trp residue. Knowledge on the mechanism of
action of these antimicrobial peptides provides information that assists in the design of antimicrobials with
higher efﬁcacy and broader spectra of action, but also on the design of peptideswith higher speciﬁcity if required.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Polycationic antimicrobial peptides (AMPs) are present in virtually
all organisms as part of the innate immune system and act as endoge-
nous antibiotics. These peptides induce the direct destruction of a
wide diversity of microorganisms [1–4]. Owing to their ability to attack
differentmicroorganisms, includingbacteria, viruses and fungi, togethericrobial peptide; AFM, atomic
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AMPs have been regarded as promising candidates for the development
of novel antibiotics [1–4]. The fact that microorganisms are less efﬁcient
in developing effective resistance mechanisms against AMPs than
against classical antibiotics [1,3,5,6] further supports the use of AMPs
as novel therapeutics. In addition, AMPs can act synergisticallywith con-
ventional antibiotics [6]. Thus, even if not used on their own, AMPs can
potentially be administered with classical antibiotics to improve their
therapeutic activity.
Cationic AMPs are generally short and amphipathic and it has been
proposed that they primarily interact with bacteria by binding to the
microbial negatively-charged membrane [7–9]. Membrane targeting is
followed by permeabilization leading to the disruption of the bacterial
membrane structure [10,11]. Alternatively, some AMPs seem to cross
the membrane without destroying it [11,12] and exert their activity
through interaction with intracellular targets (e.g. binding to and inhi-
bition of nucleic acids) [13]. Their preference for the more negatively-
charged bacterial membranes over the eukaryotic membranes, which
have an outer lipid leaﬂet globally neutral, can be responsible for their
selectivity [6,11].
Although having potential applications, naturally occurring AMPs
are susceptible to protease degradation and have low bioavailability.
In an effort to overcome these disadvantages, peptides with shorter
and improved amino acid sequences and, therefore, with increased
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and synthesized [2,4,11,14]. BP100 (KKLFKKILKYL-NH2) is a successful
example of a synthetic AMP. Obtained from a combinatorial chemistry
approach based on a cecropin A-melittin hybrid, BP100 is potent against
Gram-negative bacteria, possesses low cytotoxicity and has low suscep-
tibility to protease K degradation [14].
BP100 binds to the anionic bacterial membrane and neutralizes it
[15]. Its ability to efﬁciently disrupt anionic model membranes but not
neutralmodelmembranes, suggests that BP100 selectively disrupts bac-
teria over mammalian cells [15]. More recently, BP100 was also shown
to be able to internalize into eukaryotic cells without disrupting them
[16]. This ﬁnding holds great promise for the use of BP100 as a means
to treat eukaryotic cells that are infected with bacteria.
Although BP100 has potential application against Escherichia coli
(E. coli) [17] and other Gram-negative bacteria [14], it does not have sig-
niﬁcant activity against tested Gram-positive bacteria [17]. In theory,
the efﬁciency of AMPs can be enhanced by further improving their afﬁn-
ity for anionic membranes. Nevertheless, neither the role of the mem-
brane composition nor the structural features of peptides required for
speciﬁcity are, as yet, fully understood and predicting antimicrobial or
cytotoxic activity from a given amino acid sequence is difﬁcult.
In the present study, based on previous studies showing that Arg and
Trp residues enhance AMP activity [18,19], we propose the develop-
ment of new BP100 analogues with putative improved membrane-
binding properties: RW-BP100 (RRLFRRILRWL-NH2) and R-BP100
(RRLFRRILRYL-NH2) in which the Trp residue was replaced with a Tyr
or/and the Lys residues were replaced with Arg. The antimicrobial efﬁ-
ciency of the newly designed peptides was tested against several
Gram-negative and Gram-positive bacteria, including non-resistant
and resistant strains. Their mechanism of actionwas evaluated by direct
bacterial imaging with atomic force microscopy (AFM) and by biophys-
ical studies with model membranes. Our results show that the newly
designed peptides are not only active against Gram-negative bacteria
but also against all tested Gram-positive bacteria. This study reveals
that by replacing Lys with Arg it is possible to gain activity against
Gram-positive bacteria; this ﬁnding is very important as it provides in-
formation for AMP design where a more speciﬁc or a broader activity
is desired and also provides information on the differences in AMP ac-
tion against Gram-positive and Gram-negative bacteria.
2. Materials and methods
2.1. Peptide synthesis
BP100, R-BP100 and RW-BP100 were synthesized using microwave-
assisted solid phase using an automatic peptide synthesizer (CEMLiberty)
following standard Fmoc chemistry on a 2-chlorotrityl resin. The
deprotected peptide was cleaved using triﬂuoroacetic acid and puriﬁed
by RP-HPLC. The synthetic peptides had ≥95% purity, as conﬁrmed by
analytical RP-HPLC. Peptide concentrations were determined by absor-
bance at 280 nm assuming ε=1.49×103 M−1 cm−1 for BP100 and
R-BP100 and ε=5.50×103 M−1 cm−1 for RW-BP100. The overall hy-
drophobicity of the three peptides was compared using their RP-HPLC
retention times [20]. Samples were run using a linear AB gradient
(1% /min) at a ﬂow rate of 0.3 mL/min on a 0.3 mL analytical column.
Eluent Awas 0.05% TFA (v/v) inwater and eluent Bwas 90% acetonitrile
(v/v) and 0.05% TFA (v/v) in water.
2.2. Antimicrobial susceptibility assay
The antimicrobial activity of BP100 and its analogues was examined
by evaluation of the bacterial growth inhibition and bactericidal activi-
ty. A microtiter broth dilution method was employed [21]. Gram-
negative Escherichia coli ATCC 25922, E. coli CGSC 5167, Klebsiella
pneumoniae ATCC 13883, K. penumoniae ATCC 700603, Pseudomonas
aeroginosa ATCC 10145, P. aeroginosa ATCC 27653 and Gram-positiveStaphylococcus aureus ATCC 25923, S. aureus ATCC 33591, Streptococcus
pneumonia ATCC 33400, S. pneumonia ATCC700677, Enterococcus
faecium ATCC 35667 and E. faecium ATCC 51559 were tested. Brieﬂy,
bacterial suspensions (5×105 cells/mL) were incubated with two-fold
dilutions of peptides (solubilized in sterile water) in 96-well non-
binding surface plates (NBS, corning) for 24 h at 37 °C and compared
with antibiotics as controls (collestin for Gram-negative bacteria, and
kanamycin or tetracycline against Gram-positive bacteria). Theminimal
inhibitory concentration (MIC) was the lowest concentration showing
no visible growth. To conﬁrm if the peptides were killing the bacteria,
the minimal bactericidal concentration (MBC) was determined by
adding 30 μL of resazurin dyes (0.01% (w/v)) to each well. The plates
were incubated at 37 °C for further 18 h. Wells with blue colouration
indicate dead microorganism, whereas wells with pink colouration in-
dicate live microorganism. The MBC value is the lowest concentration
of the wells with blue colouration. The assays were done with Mueller
Hinton broth (MHB) and repeated four times.
2.3. Atomic force microscopy imaging
Direct observation of the effects induced by BP100, R-BP100 and
RW-BP100 in themorphology of bacterial cells was obtained by AFM im-
aging as previously described [17]. Cell suspensionswith 2×107 cells/mL
were spundownat 13,000 rpm(8 min for E. coli and30 min for S. aureus)
and washed twice with 10 mM phosphate buffer solution (PBS) con-
taining 150 mM NaCl, pH 7.4 to remove the media. The peptides were
incubated with the bacteria and the slides prepared as before [17].
The ﬁnal peptide concentrations were 1, 10 or 100 μM. On average, ﬁve
individual bacterial cells from two different zones of each slide with a
total area of 4×4 μm2were imaged. Height, error and phase-shift images
were recorded. Height images were treated with JPK data processing
4.0.23 and orthogonal projections were done in Gwyddion 2.24 (Czech
Metrology Institute, Czech Republic). Cross sections on ﬁve bacterial
cells were done using Gwyddion 2.24 to determine the average dimen-
sion of E. coli and S. aureus cells. The average dimensions of the non-
treated bacterial cells are in agreement with previous observations
[17,22,23] conﬁrming the viability of the controls. E. coli and S. aureus
cells had respectively 0.20±0.01 μm and 0.40±0.08 μm of height,
1.16±0.07 μm and 1.06±0.11 μm of width and 2.73±0.58 μm and
1.66±0.34 μm of length.
2.4. Bacterial surface roughness and swelling analysis of AFM images
The bacterial cell surface roughness (Rrms) was determined through
root-mean-square calculations of ﬂattened AFMheight images as previ-
ously described [17]. Changes in bacterial shape (Srms) were analysed
following a protocol similar to the one used for roughness [17] but in-
stead of using a ﬂattened representation of the bacterial cell surface, a
mean-ﬁlter treated AFM image of the general shape of the bacteria
was used. With this treatment it was possible to remove the superﬁcial
bacterial roughness and analyse the general shape and volume of the
bacteria. The Srms was calculated using Eq. (1) [17]. Non-treated and
peptide-treated bacteria were compared.
Srms ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑Ni¼1
Zi−Zmð Þ2
N−1ð Þ
s
ð1Þ
2.5. Haemolytic assay
The haemolytic activity of the peptides was determined using
human red blood cells (RBCs) as described before [24]. Brieﬂy, peptides
were solubilized in 10 mM HEPES buffer containing 150 mM NaCl, pH
7.4 and tested in triplicates (two-fold dilutions starting with 50 μM).
Melittin, a peptidewith knownhaemolytic propertieswas also included
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X-100 were used to establish 0% or 100% of haemolysis, respectively.
The experiment was repeated three times. The peptide concentration
needed to achieve 50% of haemolysis (HC50) was determined as before
[24].
2.6. Cytotoxicity against human cells
Cervical cancer cells (HELA) were cultured in T175 ﬂasks at 37 °C in
an atmosphere of 5% CO2 with DMEM containing 10% FBS. Cells were
seeded (5×103 cells/ well) in 96-well plate ﬂat-bottomed plate for
24 h before assay. BP100 and its analogues were incubated for 2 h in
concentrations ranging from 60 to 0.5 μM, ﬁnal volume 100 μL in
media without serum, to avoid degradation. Blank without peptide,
and cells with Tx-100 were included to establish 0% and 100% of cell
death. After incubation, peptides were washed with PBS, fresh media
(100 μL) containing serum and 10 μL resazurin dye (0.02% (w/v))
were added to the cells and incubated for 18 h. Absorbance signal was
monitored at 540 and 620 nm and the percentage of death cells was
quantiﬁed by calculating the absorbance ratio, R, (R=A620/A540 nm)
and considering 100% of cell death the R obtained with TX-100 and 0%
of death the R obtained with cells without compound, using the equa-
tion:
% Cell death ¼
Rsample−Rblank
 
RTX−100−Rblankð Þ
 100 ð2Þ
2.7. Binding afﬁnity for lipopolysaccharide and lipotheicoic acid
The endpoint Chromogenic Limulus Amebocyte Lysate (LAL) test kit
(QLC-1000, Lonza) was employed to examine the ability of BP100 and
its analogues to neutralize lipopolysaccharide (LPS) and lipoteichoic
acid (LTA). This test is a sensitive indicator of the presence of free,
non-neutralized endotoxin (either LPS or LTA) [25]. LPS from E. coli
O111:B4 (standardprovidedwith the LAL assay kit) or LTA from S. aureus
(L2515 from Sigma) were incubated with various concentrations of
BP100 and its analogues. Brieﬂy, peptide and LPS (1 EU/mL), or LTA
(500 ng/mL, response equivalent to LPS 1 EU/mL), were incubated for
30 min to allow binding. LAL reagent was added and incubated for
10 min at 37 °C, followed by addition of the colourless substrate and
incubation for further 6 min as per manufacture instructions. The reac-
tion was stopped with 25% (v/v) glacial acetic acid and the release of
p-nitroaniline followed by absorbance at 405 nm. Controls with water
or peptide only were included to conﬁrm that all the samples were
endotoxin-free. After blank subtraction, the concentration of free endo-
toxin was calculated by using calibration curves obtained with LPS
(0.125–1 EU/mL) or LTA (62.5–1000 ng/mL). The values were normal-
ized and converted into bound endotoxin (bound endotoxin=1−free
endotoxin) and plotted as a function of peptide concentration. The ex-
periment was repeated three times.
2.8. Preparation of lipid vesicles
Large unilamellar vesicles (LUVs) with a diameter of 100 nm, or
small unilamellar vesicles (SUVs) with a diameter of 50 nm were used
as membrane model and prepared by extrusion method as before
[26]. LUVs were used in ﬂuorescence studies whereas SUVs were used
to prepare the bilayers for surface plasmon resonance studies [27]. Ves-
icles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC; Avanti Polar Lipids, USA) or with mixtures of POPC and
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) were pre-
pared for comparison. All the lipid systems were prepared in 10 mM
HEPES buffer, pH 7.4 containing 150 mM NaCl.2.9. Binding of BP100 and analogues with lipid bilayers followed by SPR
The ability of BP100 and its analogues to bind to phospholipid lipid
bilayers was examined using SPR as described for other peptides [27].
L1 sensor chips and a Biacore 3000 instrument were used. The binding
of the three peptides was compared for POPC, POPC/POPG (4:1 molar
ratio) and POPC/POPG (1:1 molar ratio). Each measurement was re-
peated three times. The obtained sensorgrams were normalized for
lipid deposition and peptide mass and represented as peptide-to-lipid
ratio (P/L). The relative afﬁnitywas compared based on the P/L obtained
at a reporting point at the end of the association phase (t=170 s) [28].
2.10. Changes in membrane dipole potential
Themembranedipole potential can change upon insertion of peptide
into the lipid membrane. Changes in model membranes dipolar
potential were followed with ﬂuorescence excitation spectra of the
membrane dye (4-[2-[6-(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-
sulfopropyl) (di-8-ANEPPS; Invitrogen, USA)) as before [27]. The dye
(4 μM) was added to 200 μM POPC or POPC/POPG (1:1 molar) LUVs
and incubated overnight. The ﬂuorescence excitation spectra (λem=
613 nm for POPC and λem=617 nm for POPC/POPG vesicles) were
recorded before and after peptide addition (12.5, 25 and 50 μM, incubat-
ed for ~5 min).
Dipole potential variations in Human cells membranewere alsomon-
itored using RBCs and peripheral blood mononuclear cells (PBMCs) and
the samepeptide concentrations. Cell isolation anddye-labelling followed
protocols previously described [29].
2.11. Vesicle aggregation
Vesicle aggregation induced by BP100, R-BP100 or RW-BP100 was
followed by optical density at 436 nm (OD436) [26]. The peptide (6.25,
12.5, 20, 25 and 50 μM) was added to POPC or POPC/POPG (4:1 or 1:1
molar) vesicles (500 μM ﬁnal lipid concentration) and the OD followed
as a function of time.
2.12. Vesicle leakage studies
Leakage of vesicle contents induced by BP100, R-BP100 and
RW-BP100 was quantiﬁed by carboxyﬂuorescein (CF) ﬂuorescence
dequenching (lipid vesicles were prepared with 50 mM of CF solubi-
lized in 10 mMHEPES buffer containing 150 mM NaCl). Vesicle prepa-
ration, lipid quantiﬁcation and determination of leakage percentage
followed protocols previously described [30]. Different peptide concen-
trations with two-fold dilutions starting from 100 μM were incubated
with POPC or POPC/POPG (1:1 molar) LUVs (50 μM, ﬁnal lipid concen-
tration). The ﬂuorescence intensity (λexc=492 nm, λem=518 nm)
was measured after 5 min incubation and LC50 (peptide concentration
needed to induce 50% of leakage) calculated as before [30]. The leakage
kineticwas followed for 150 s after addition of peptide (25 μM) to POPC
or POPC/POPG (1:1molar) vesicles (50 μM lipid concentration) and the
time necessary to achieve half of the response (T1/2) was determined
considering a pseudo-ﬁrst order kinetic.
2.13. The ﬂuorescence properties of BP100 and its analogues in aqueous
solution and in membrane environment
Thepeptides included in this study have intrinsicﬂuorescence due to
the presence of a Tyr (BP100 and R-BP100) or Trp residue (RW-BP100)
in their sequence. Unless otherwise stated, BP100 and R-BP100were ex-
cited at 274 nm and RW-BP100 was excited at 280 nm. Fluorescence
emission spectra were scanned as a function of peptide concentration,
pH andurea concentration. The existence of red-edge excitation shift ef-
fect (REES) was studied for RW-BP100: ﬂuorescence emission spectrum
was followed upon excitation with different wavelengths in the range
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ment was evaluated by ﬂuorescence emission quenching upon titration
with acrylamide, as before [31]. To minimize the relative quencher/
ﬂuorophore light absorption ratio BP100 and R-BP100 were excited at
274 nmwhereas RW-BP100 was excited at 290 nm. Fluorescence spec-
tra with a bandwidth of 5/10 nm for BP100 and R-BP100, or 3/6 nm for
RW-BP100, were acquired at 25 °C in a spectroﬂuorimeter Edinburgh
FS900 with 0.5 cm length quartz cuvettes. Peptides were solubilized in
10 mM HEPES buffer, pH 7.4 containing 150 mM NaCl.
To evaluate if the Trp or Tyr residue inserts in the lipid bilayer, the
partition of BP100 and its analogues was followed by peptide ﬂuores-
cence emission. Peptides were titrated with POPC or POPC/POPG (4:1
or 1:1 molar ratio) vesicle suspensions (ﬁnal lipid concentrations in
the range 0–4 mM). All the sampleswere incubated for ﬁveminutes be-
fore spectra scanning. To have negligible inner ﬁlter effect, the experi-
ment was performed with 50 μM BP100 or R-BP100 and 15 μM of
RW-BP100 (absorbanceb0.1). The integrated area of each ﬂuorescence
spectrum was corrected for dilution and light dispersion, was normal-
ized for the signal in buffer (I/IW) and plotted as a function of lipid con-
centration [32]. The partition coefﬁcient, Kp, and the ratio of the
ﬂuorescence emission obtained when all the peptide molecules are
partitioned in the lipid (IL) to the ﬂuorescence intensity when all the
peptide molecules are in water environment (IW), IL/IW, were deter-
mined by ﬁtting a non-linear equation as previously detailed [32].
2.14. Peptide in-depth location in lipidic membranes
Themembrane in-depth location of the Trp or Tyr residue in the test-
ed peptides was determined by a differential ﬂuorescence quenching
approach as previously described [33]. Brieﬂy, quenching of peptide
ﬂuorescence emission was evaluated in the presence of quenchers (ac-
rylamide, 5- and 16- doxyl stearic acid (5- and 16-NS)) that localize
with different depths in the membrane [33]. 50 μM of BP100 and
R-BP100 or 15 μM of RW-BP100 was incubated with 3 mM POPC or
POPC/POPG (1:1) vesicles and titrated with increasing concentrations
of acrylamide, 5- or 16-NS (Sigma-aldrich, USA) as detailed elsewhere
for other peptides [31]. Data were analysed using the Stern–Volmer
equation and quenching efﬁciency quantiﬁed with KSV (Stern–Volmer
constant) [31].When a positive deviation to the Stern–Volmer represen-
tation was observed data were analysed as sphere-of-action quenching
[34].
2.15. Secondary structure followed by circular dichroism (CD) spectroscopy
CD spectra were obtained on a Jasco J-815 instrument (Jasco Co,
Tokyo, Japan) using a 1 mm path length cuvette. Brieﬂy, spectra were
collected from 195 to 260 nm at a speed of 50 nm/min. Peptide and
lipid samples were prepared in 10 mM phosphate buffer with 150 mMFig. 1. Theoretical prediction of the afﬁnity of the peptides for the membrane environment. The fr
branes interface (ΔGwater–membrane interface) is represented based onWimley &White amino acid in
ﬁnity for the membrane interface region than for the aqueous environment. The new derivatives,
RW-BP100 also has the Tyr residue replaced with a Trp residue (shaded bar). The residues that wNaF, pH 7.4. The CD signal of the peptides (50 μM) was recorded in the
absence/presence of POPC or POPC/POPG (1:1) vesicles (peptide-to-lipid
ratio was 1:9 molar or 1:19molar depending on the signal intensity and
vesicles dispersion contribution). To evaluate the effect of low pH and of
a denaturizing agent in the peptides structure, the peptide CD signal was
also evaluated at pH 2 and in the presence of 5 mM urea. Spectra were
corrected by subtracting the appropriate blank (buffer, lipid in buffer,
urea in buffer or buffer at pH 2) and converted tomean residuemolar el-
lipticity. Spectra were smoothed using the noise reduction routines pro-
videdwith the J-815 spectropolarimeter software (using Savitzky–Golay
method). A quantitative analysis of the percentage of helicity was
performed using three deconvolution software packages (SELCON3,
CONTINLL and CDSSTR). No agreement was obtained between the
three packages, and therefore a quantitative analysis was not included.
3. Results
3.1. Design of BP100 derivatives and their hydrophobic and basic properties
BP100 [14], like many other antimicrobial peptides (e.g. cecropins,
magainins, cathelicidins and defensins) [35], kills bacteria through
targeting membranes. The aim of the present study was to improve
the activity of BP100 by modulating its membrane-binding properties
and to gain more insights into the importance of basic and hydropho-
bic residues for antimicrobial efﬁcacy and spectrum of action. There-
fore, two new BP100 analogues, RW-BP100 and R-BP100 (Fig. 1), in
which the Tyr residue is replaced with a Trp residue and/or the Lys
residues were replaced with Arg residues, were designed. The global
charge is +6 for the three peptides and the overall hydrophobicity,
as measured with RP-HPLC retention times (36.6 min for BP100,
37.7 min for R-BP100 and 40.4 min RW-BP100), follows the order
BP100bR-BP100bRW-BP100.
The putative membrane-binding afﬁnity trend of the three peptides
was estimated using the Wimley & White membrane interface hydro-
phobic scale [36]. Most hydrophobic scales focus on the membrane hy-
drophobic bulk phase [37], whereas theWimley &White scale predicts
the partition of thewhole residue fromwater to the phospholipidmem-
brane interfaces [38], which is particularly relevant to predict the ability
of a peptide to target membranes. The membrane-binding partition as
estimated by Wimley & White scale suggests the following trend:
BP100bR-BP100bRW-BP100 (see Fig 1).
3.2. Newly designed AMPs have higher antimicrobial activity than BP100
The antimicrobial activities of BP100, R-BP100 and RW-BP100 were
tested against Gram-negative and Gram-positive bacterial strains
(Table 1). These bacteria have pathological interest and possess strains
with antibiotic resistance and therefore they were chosen as models ofee transfer energy of (A) BP100, (B) R-BP100 and (C) RW-BP100 fromwater to POPCmem-
terfacial hydrophobic scale [36]. Amino acids withΔGwater–membrane interfaceb0 have higher af-
R-BP100 and RW-BP100, have the Lys residues mutated with Arg residues (white bars) and
ere not mutated are represented with black bars.
Table 1
Antimicrobial activity of BP100, R-BP100 and RW-BP100.a
MIC (μM)b MBC (μM)c
Bacterial strain and species Relevant feature BP100 R-BP100 RW-BP100 BP100 R-BP100 RW-BP100
Gram negative
Escherichia coli ATCC 25922 control 2.0±0.0 0.9±0.4 0.5±0.2 3.0±0.6 1.1±0.3 1.3±0.3
Escherichia coli CGSC 5167 resistant, LPS mutant 0.7±0.2 0.4±0.1 0.2±0.1 1.3±0.5 0.5±0.0 0.3±0.1
Klebsiella pneumoniae ATCC 13883 control 1.0±0.0 0.3±0.2 0.1±0.0 3.5±0.5 0.4±0.1 0.4±0.1
Klebsiella pneumoniae ATCC 700603 multiresistant 4.0±0.0 0.6±0.3 0.3±0.0 4.0±0.0 2.1±0.7 0.9±0.1
Pseudomonas aeruginosa ATCC 10145 control 8.0±0.0 2.0±0.0 2.5±0.5 8.0±0.0 4.5±1.3 3.5±0.5
Pseudomonas aeruginosa ATCC 27853 resistant 4.0±0.0 1.5±0.3 1.5±0.3 4.0±0.0 1.5±0.3 1.8±0.3
Gram positive
Staphylococcus aureus ATCC 25923 control 32.0±0.0 6.0±1.2 0.8±0.1 32.0±0.0 8.0±0.0 1.0±0.0
Staphylococcus aureus ATCC 33591 resistant 16.0±0.0 3.0±0.6 0.3±0.1 28.0±4.0 4.0±0.0 0.6±0.1
Streptococcus pneumoniae ATCC 33400 control 32.0±0.0 5.0±1.0 0.8±0.1 32.0±0.0 7.0±1.0 1.0±0.0
Streptococcus pneumoniae ATCC 700677 resistant 16.0±0.0 4.0±0.0 0.4±0.1 28.0±4.0 6.0±1.2 0.9±0.1
Enterococcus faecium ATCC 35667 control 32.0±0.0 4.0±0.0 1.0±0.0 32.0±0.0 4.0±0.0 1.1±0.3
Enterococcus faecium ATCC 51559 multiresistant 16.0±0.0 2.0±0.0 1.0±0.0 16.0±0.0 2.0±0.0 1.0±0.0
aThe antimicrobial activity was determined in MHB. bMIC is the lowest concentration showing no visible growth. cMBC is the lowest concentration required to kill all the cells as
measured with resazurin dye. The values shown are the average and standard error of four replicates.
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were included for comparison. BP100 was active at low micromolar
concentrations against all the Gram-negative bacteria tested (control
and resistant strains) but has lower efﬁcacy against Gram-positive bac-
teria, which is in agreement with previous reports [17,39]. The newly
designed peptides were more active against Gram-negative bacteria
than BP100, butmost importantly are active at lowmicromolar concen-
tration against all tested Gram-positive bacteria. RW-BP100 is the most
active derivative, particularly against Gram-positive bacteria. It is worth
noting that RW-BP100 has a MIC below 1 μM against tested resistant
strains of E. coli, S. aureus, K. pneumonia and S. pneumonia. The deter-
mined MBC values are close to the MIC, revealing that the peptides are
bactericidal and inhibit the bacterial growth by killing the bacteria.
Direct observation of the effects induced by BP100 and the two ana-
logues was obtained by AFM imaging (Fig. 2). E. coli and S. aureuswere
used as models of Gram negative and Gram positive bacteria, respec-
tively. BP100 and its analogues show identical effects on E. colimorphol-
ogy. E. coli cells treated with 1 or 10 μM of peptide have their volume
increased (Fig. 2E) and develop round-shaped structures on the mem-
brane surface (Fig. 2A), which increase the overall surface roughness
(Fig. 2C). When treated with 100 μM of BP100, or the analogues, the
E. colimembrane is disrupted and the intracellular contents leak exten-
sively (see Fig. 2A). These effects are in agreement with a previous re-
port on BP100 [17].
Effects on S. aureus cell morphology, roughness and volume (Fig. 2B,
D,F) were evident with R-BP100 and RW-BP100 at concentrations
≥10 μM, whereas BP100 only has visible effects at 100 μM. Membrane
disruption of S. aureus is evident for all the peptides at the highest con-
centration tested.3.3. Cytotoxicity and therapeutic index of BP100 and its analogues
The cytotoxicity of the peptideswas assessed in HELA cells (Fig. 3A),
revealing that BP100 is the least toxic peptide and RW-BP100 is the
most toxic. Although being the most cytotoxic peptide, RW-BP100 has
the highest therapeutic index (TI, i.e., the ratio of toxic dose to therapeu-
tic dose (IC50/MIC)) against Gram positive bacteria, whereas BP100 has
the lowest TI (e.g. the TI of BP100, R-BP100 and RW-BP100 against the
resistant S. aureus strain ATTC 33591 is 3, 6 and 48, respectively).
When comparing the TI for Gram negative bacteria the three peptides
have a therapeutic index≥10 for all the resistant bacteria strains tested.
Haemolytic studies were also carried and showed that RW-BP100 is
the most haemolytic peptide whereas BP100 has low haemolytic activ-
ity in the concentration range tested (see HC50 in Fig. 3B).3.4. Binding to LPS and LTA
The outer membranes of Gram-positive and Gram-negative bacteria
differ signiﬁcantly in their composition, which could explain the selec-
tivity of BP100 towards Gram-negative bacteria. In addition to a thicker
peptidoglycan layer, Gram-positive bacteria have LTA exposed in the
outer membrane, whereas Gram negative bacteria have a thin peptido-
glycan layer and an outer lipid bilayer covered with LPS [40]. These
negatively-charged molecules activate multiple signal transduction
pathways and constitute the ﬁrst physical barrier which needs to be
transversed by antimicrobial peptides [41]. Therefore, the ability of
BP100 and its analogues to bind to LPS and LTAwas examined and com-
pared using a LAL assay. Fig. 4 shows that the three peptides are able to
bind and neutralize LPS and LTA, but BP100 has the weakest activity.
R-BP100 and RW-BP100 have identical activity to neutralize both
molecules.
3.5. BP100 and its analogues have preference for negatively-charged
membranes as identiﬁed by SPR
The ability of BP100 and its analogues to bind to phospholipid bilay-
erswas examined using SPR to gain insights into theirmechanismof ac-
tion (Fig. 5).Membranes composed of zwitterionic POPC,whichmimics
the bulkﬂuid phase in eukaryotic cell membranes, were comparedwith
POPC/POPG mixtures to mimic anionic bacterial cell membranes. SPR
studies conﬁrmed that BP100 has the lowest afﬁnity for the membrane
whereas RW-BP100 has the highest afﬁnity. The three peptides have a
preference for more anionic membranes relative to zwitterionic mem-
branes (Fig. 5C). The preference of BP100 for more anionic membranes
in relation to neutral membranes is in agreement with a previous study
[15]. As predicted using the Wimley & White amino acid hydrophobic
scale (see Fig. 1), the new derivatives have higher afﬁnity for mem-
branes than BP100.
3.6. Changes in the dipolar potential induced by BP100 and its analogues
Changes in the membrane dipole potential might occur upon inser-
tion of peptides into phospholipid bilayers and can bemonitored through
spectral shifts in the ﬂuorescence excitation spectra of di-8-ANEPPS
probe [42]. The three peptides induced a larger change in the dipolar po-
tential of POPC/POPG (1:1) than in POPC membranes (Fig. 6A & B),
conﬁrming a preference for negatively-charged membranes in respect
to zwitterionic membranes. In addition, changes in dipolar potential re-
veal that these peptide molecules are inserting in the anionic lipid mem-
branes rather than just being adsorbed at the phospholipid headgroup
Fig. 2. The effect of BP100, R-BP100 and RW-BP100 on E. coli and S. aureus cells as monitored by AFM. (A, B) Orthogonal tridimensional projections of E. coli (A) and S. aureus (B) cells incubated for 2 h in the absence (control) or in the
presence of 1, 10 or 100 μM of peptide. Images have a total area of 4×4 μm2. (C, D) Differences in the superﬁcial roughness and (E, F) in bacterial shape of E. coli and S. aureus cells were determined through root-mean-square calculation
(Rrms and Srms, respectively). For each peptide concentration ﬁve bacterial cells were analysed. Asterisks represent the signiﬁcance level of the difference between treated and non-treated bacterial cells. A one-way ANOVA and a Bonferroni
test were employed. * 0.01bp-valueb0.05; ** 0.001bp-valueb0.01 and *** p-valueb0.001.
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Fig. 3. Cytotoxicity and haemolytic activity of BP100 and its analogues. (A) Cytotoxicity dose
response curves obtained against HELA cells as measured with a resazurin assay. Peptides
were incubated with HELA cells for 2 h at 37 °C in medium without serum. The % of dead
cells was determined by absorbance of the ratio of reduced/oxidized dye. The concentration
needed to achieve 50% of cell death (IC50) as obtained by a non-linear ﬁt of the data was
49.2±1.4, 17.5±0.6 and 14.4±0.4 μM for BP100, R-BP100 and RW-BP100, respectively.
(B)Haemolysis dose response curves obtained after incubation of 0.25% (v/v) RBCswith pep-
tide for 1 h at 37 °C; HC50 is >100 μM for BP100, 50.9±25.0 μM for R-BP100 and 4.9±
1.0 μM for RW-BP100. Error bars represent standard error of the mean for three replicates.
950 I.M. Torcato et al. / Biochimica et Biophysica Acta 1828 (2013) 944–955region. RW-BP100 induced the largest change in the dipole potential in
both lipidic mixtures studied (POPC and POPC/POPG 1:1). Signiﬁcant al-
terations in the RBC's or PBMC's membrane dipole potential were not
detected for any of the analogues (data not shown) at concentrations
higher than theMIC (12.5, 25 and 50 μM), suggesting that these peptides
do not insert signiﬁcantly into human cells.
3.7. Vesicle aggregation and leakage induced by BP100 and its analogues
Themembrane surfaces of vesicles can be brought in close proximity
due tomembrane–peptide–membrane interactions, resulting in vesicle
aggregation [43]. The stability of vesicles dispersed in solution is mainly
maintained by repulsive electrostatic forces and a repulsive hydration
shell [43]. The interactions of positively-charged peptides with the
negatively-chargedmembranes can cancel repulsive electrostatic forcesFig. 4.Neutralizationof LTAand LPS in thepresenceof BP100or its analogues. Peptideswere incub
fractionof boundendotoxin as a functionof peptide is shown.KD is thepeptide concentration requi
represent standard error of the mean of three replicates.and induce dehydration of the lipid polar groups. Such alterationsmake
the surface more unstable and facilitate the aggregation of the vesicles
[43]. The three peptides are able to induce aggregation of POPC/POPG
(1:1) vesicles but not of the vesicles composed with POPC or POPC/
POPG (4:1) (up to P/L=0.1, Fig. 6C). These results support the ﬁnding
that all three peptides prefer more negatively-charged membranes
over neutral membranes and show that the membrane surface is dis-
turbed upon peptide binding. BP100 showed the highest ability to
induce aggregation of POPC/POPG (1:1 molar) vesicles at 25 μM, sug-
gesting that this peptide more efﬁciently disturbs the membrane sur-
face than the other two peptides. RW-BP100 showed the weakest
vesicle surface destabilization ability.
It was previously reported that BP100 makes lipid vesicles perme-
able to Co2+ ions [15]. In the present study we evaluated the leakage
of contents from POPC or POPC/POPG (1:1) vesicles induced by BP100
and its analogues (Fig. 6D and Table 2). Vesicles loaded with CF (ﬁnal
lipid concentration of 50 μM) were incubated with varying concen-
trations of peptide (up to P/L of two). BP100 and its analogues induce
leakage of the anionic POPC/POPG (1:1) vesicles with identical efﬁ-
ciency (Table 2; LC50~5 μM, P/L~0.1). RW-BP100 induces vesicle
leakage at a faster rate than the other peptides, (see Fig. 6D and T1/2
values in Table 2). A faster leakage rate might correlate with a faster
membrane-binding rate.
Leakage from POPC vesicles occurs at a lower extension (Fig. 6D)
and the efﬁciency is peptide dependent, being BP100 the least and
RW-BP100 the most effective (Table 2). This trend is expected consid-
ering the haemolytic proﬁle of the three peptides.
3.8. Fluorescence properties of BP100 and its analogues in buffer and in
the presence of the lipid bilayer
BP100 and its analogues are intrinsically ﬂuorescent due to Tyr or Trp
residues in their sequence. The ﬂuorescence of these aromatic residues is
sensitive to its environment; therefore, the intrinsic steady-state ﬂuores-
cence properties can give insights into the structure and organization of
the peptides in the aqueous environment. BP100 and R-BP100 have exci-
tation and emission spectra similar to L-Tyr amino acid (λexcitation maxi-
mum=275 nmandλemissionmaximum=302 nm),whereas RW-BP100
has excitation and emission spectra identical to L-Trp amino acid in buff-
er (λexcitation=280 nm and λemission=347 nm). These spectral charac-
teristics suggest that BP100 and its analogues have the Tyr or Trp
residue exposed to the solvent [44]. This ﬁnding is supported by the ob-
servation that the ﬂuorescence quantumyield is independent of the pep-
tide concentration (at least up to 100 μM)and independent of pH (as low
as 2.5, data not shown). Due to the high sensitivity of Trp to the sur-
rounding environment, the ﬂuorescence of Trp-containing peptides
might have REES as a result of peptide aggregation; this phenomenon
is not so easily detected with Tyr ﬂuorescence [44]. RW-BP100 ﬂuores-
cence does not showREES,which supports a non-aggregatedﬂuorophoreatedwith endotoxin for 30 min and the amount of free endotoxinquantiﬁedby LAL assay. The
red to neutralize 50%of endotoxin andwasdeterminedbynon-linearﬁt of thedata. Error bars
Fig. 5.Membrane-binding afﬁnity of BP100 and its analogues asmonitored by surface plasmon resonance. The response to the total amount of lipid deposited on the chip surfacewas normal-
ized by calculating the peptide-to-lipid ratio (P/L mol/mol) (1RU=1 pg·mm−2). Sensorgrams obtained upon injection of 10 μM peptide over (A) POPC or (B) POPC/POPG (1:1) bilayers. (C)
Comparison of the P/L obtained for the three peptides at a reporting point at the end of the association phase over POPC, POPC/POPG (4:1) or POPC/POPG (1:1) bilayers. Error bars represent
standard error of the mean of three replicates.
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that BP100 and its analogues are non-structured and do not aggregate
in aqueous solution.
Theﬂuorescence emission quantumyield of the Tyr residue in BP100
or R-BP100 and of the Trp residue in RW-BP100 increased upon titration
with lipid vesicles. In addition, RW-BP100 emission spectra have a blue
shift characteristic of Trp residue transition from aqueous environment
to a more hydrophobic environment [44]. Such alterations in the Tyr/
Trp ﬂorescence suggest that these residues insert into the lipid bilayer.
Therefore, the Tyr/Trp ﬂuorescence emission can be used to quantify
the relative afﬁnity of these residues for lipid membranes through theFig. 6. Changes in membrane properties due to interaction with BP100 and its analogues. (A, B)
200 μM of (A) POPC or (B) POPC/POPG (1:1 molar) vesicles. The ﬁnal concentration of the di-
POPC/POPG (1:1 molar) than in POPC vesicles. RW-BP100 induces the largest dipolar potential v
BP100, R-BP100 or RW-BP100 to 500 μMof POPC/POPG (1:1 molar) vesicles, or 50 μMof BP100 t
No aggregation and, therefore, no increase inODwas observed for POPC or POPC/POPG (4:1) vesic
leakage inducedby 25 μMofBP100, R-BP100 andRW-BP100 in the presence of 50 μMPOPC/POPG
converted into % of leakage; TX-100 0.1% (v/v) was added at the end of each kinetics (not showndetermination of the partition coefﬁcient, Kp [32]. In the three peptides
the hydrophobic region binds with higher afﬁnity to membranes with
higher percentage of negatively-charged phospholipids, relative to
zwitterionicmembranes, as shownwith Kp values (Table 3). In addition,
at a ﬁxed lipid concentration the ﬂuorescence emission spectra of
RW-BP100 have a larger blue-shift in POPC/POPG (1:1) relative to
POPC membranes (e.g. 18 nm in 1 mM POPC/POPG (1:1) vs. 10 nm in
1 mM POPC). The trend observed for IL/IW (the ratio of the ﬂuorescence
emission obtained when all the ﬂuorophores are partitioned in the lipid
(IL) to the ﬂuorescence intensity when all the ﬂuorophores are in water
(IW)) is BP100~R-BP100bRW-BP100 suggesting that RW-BP100 has itsMembrane dipole potential variation induced by 50 μM of BP100, R-BP100 or RW-BP100 in
8-ANNEPS probe was 4 μM. All the peptides induce a larger dipolar potential variation in
ariation. (C) Vesicle aggregation studies. OD436nm was monitored after addition of 25 μM of
o POPC or POPC/POPG (4:1 molar) vesicles. The OD values were normalized for the baseline.
les. The three peptides induce aggregation of POPC/POPG (1:1) vesicles. (D) Kinetics of vesicle
(1:1molar) and POPC vesicles, as followedbydequenching of CF. Theﬂuorescence signalwas
) to establish 100% of leakage in each assay.
Table 2
Vesicle leakage induced by BP100, R-BP100 and RW-BP100.a
Peptide Lipid mixture LC50±SE (μM) b T1/2±SE (s)c
BP100 POPC >100 6.21±0.30
POPC/POPG (1:1) 3.71±0.11 4.85±0.04
R-BP100 POPC 83.28±8.89 3.67±0.23
POPC/POPG (1:1) 5.06±1.66 0.37±0.04
RW-BP100 POPC 10.71±0.67 0.63±0.07
POPC/POPG (1:1) 5.16±0.34 0.14±0.01
aPeptides were incubated with vesicles suspensions containing 50 μM of total lipid
concentration. bThe peptide concentration needed to achieve 50% leakage (LC50) and
the standard errors were determined by ﬁtting a non-linear regression equation in
which the maximum response was ﬁxed to 100% leakage. cTime required to achieve
half of the maximum response upon addition of 25 μM of peptide to lipid suspension
containing 50 μM of lipid.
Table 4
Emission ﬂuorescence quenching of BP100, R-BP100 and RW-BP100 induced by 5-NS,
16-NS or acrylamide.a
Peptide Lipid mixture KSV, 5-NS
(M−1)
KSV, 16-NS
(M−1)
KSV, acrylamide
(M−1)
BP100 POPC 0.80±0.16 0.55±0.23 9.60±0.82
POPC/POPG (1:1) 2.47±0.06 2.02±0.06 1.94±0.29
Buffer 34.10±1.57
R-BP100 POPC 1.36±2.10b 0.21±0.22 4.88±0.30
POPC/POPG (1:1) 1.88±0.09 1.72±0.15 1.37±0.26
Buffer 8.80±0.22
RW-BP100 POPC 7.48±1.47 2.86±0.34 4.79±0.34
POPC/POPG (1:1) 0.68±0.24 2.19±0.27 3.23±0.21
Buffer 18.40±0.63
aEach peptide was titrated with a quenching agent (5-NS, 16-NS or acrylamide) in the
presence or absence of LUVs and quantiﬁed by Stern–Volmer constant, KSV. KSV and
standard errors were determined by ﬁtting the Stern–Volmer equation. bStern–Volmer
representation shows a positive deviation, therefore KSV was determined by ﬁtting a
quenching with sphere-of-action.
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R-BP100 or in BP100 peptide.
3.9. Membrane in-depth location of BP100 and its analogues
The location of the Tyr/Trp residue when the peptides are bound to
the membrane was monitored by a differential quenching approach. 5-
and 16-NS are stearic acidmolecules derivatized (carbon 5 or 16)with a
doxyl group, a quencher of the Tyr and Trp ﬂuorescence. With a differ-
ential depth location in the membrane, the doxyl group in 5-NS more
efﬁciently quenches ﬂuorophores located in the water–membrane in-
terface, whereas 16-NS is more efﬁcient as a quencher of ﬂuorophores
more deeply inserted [33]. In addition, acrylamide, a soluble quencher
unable to partition extensively into lipidic membranes, was used to
quench ﬂuorophores accessible to the aqueous environment [31] and
its quenching efﬁciency was measured in the absence and presence of
LUVs suspension.
The relative quenching efﬁciency can be compared with the Stern–
Volmer constant, KSV (Table 4). All of the peptides tested were more ef-
ﬁciently quenched by acrylamide in the absence of model membranes
than in their presence, suggesting that the peptides are inserted into
the lipid bilayer and less accessible to the aqueous environment. In ad-
dition, the ﬂuorescence of all the peptides is more efﬁciently quenched
in the presence of POPC/POPG (1:1molar) relative to POPCmodelmem-
branes, which conﬁrms better insertion into negatively-charged than
into zwitterionic membranes.
In POPC membranes all of the peptides have the ﬂuorescent residue
more accessible to 5-NS than to 16-NS, suggesting a location in the in-
terface. In POPC/POPG (1:1) membranes, RW-BP100 is more efﬁciently
quenched by 16-NS than 5-NS, suggesting a deeper insertion, whereas
the ﬂuorescence of BP100 or R-BP100 is quenched by 5- and 16-NS
with identical efﬁciency. A deeper insertion of RW-BP100 into POPC/
POPG (1:1) membrane is consistent with the larger change in the dipo-
lar potential (see Fig. 6B) and lower surface destabilization observed by
aggregation studies, when comparedwith the other two analogues (see
Fig. 6C). Altogether these results show that the Tyr/Trp region of theTable 3
Afﬁnity of BP100, R-BP100 and RW-BP100 for different lipid mixtures.a
Peptide Lipid mixture Kp (×103) IL/IW
BP100 POPC 0.26±0.9 2.11±1.86
POPC/POPG (4:1) 1.19±0.17 2.12±0.67
POPC/POPG (1:1) 3.97±1.05 2.27±1.27
R-BP100 POPC 1.51±0.11 2.51±0.42
POPC/POPG (4:1) 3.54±0.36 2.86±0.62
POPC/POPG (1:1) 6.26±0.96 2.72±0.88
RW-BP100 POPC 1.12±0.06 4.30±0.59
POPC/POPG (4:1) 3.09±0.56 3.98±1.62
POPC/POPG (1:1) 27.9±7.90 3.41±1.99
a Peptides were titrated with LUV suspensions and the ﬂuorescence emission signal
(I/IW) plotted as a function of lipid concentration. The Kp and IL/IW parameters were
obtained from ﬁtting a non-linear equation.molecule can insert in the hydrophobic region of the phospholipid
membrane.
3.10. CD spectroscopy in the presence of membrane vesicles
To analyse the structure of the peptides in aqueous solution and in
the presence of lipid membrane we performed CD measurements
(Fig. 7). In buffer all peptides had very low ellipticity above 210 nm
and a strong negative band near 195 nm, which is typical of a random
coil structure [45]. A lack of structure was conﬁrmed in the presence
of urea, a denaturizing agent. No alterations in CD signals were detected
for any of the peptides, even with concentrations as high as 5 M urea
(data not shown). In addition, all the peptides maintained a random
coil conformation in buffer with pH 2 (data not shown).
In the presence of anionic vesicles the three peptides show a tran-
sition from unstructured to helical form, revealing a change in confor-
mation uponmembrane insertion. With POPC no alterations in the CD
signal were detected, suggesting the requirement of anionic phos-
pholipids for an alteration in the conformation. A helical wheel con-
formation suggests an amphipathic structure with the nonpolar
residues in one side and the positive side chains in the other face of
the helix.
4. Discussion
In this study we designed two new AMPs, R-BP100 and RW-BP100,
and compared their antimicrobial activities and toxic properties with
the parent analogue BP100. Atomic force microscopy with bacterial
cells and biophysical studies with model membranes were employed
to gain insights on themechanism of action of BP100 and its analogues.
MIC andMBC assays revealed that the newly designedAMPs aremore
active thanBP100, previously reported to be active againstGram-negative
bacteria [14] but inactive against the Gram-positive S. aureus [17]. Here
we show that R-BP100 and RW-BP100 were not only active against
Gram-negative bacteria, but also had activity against Gram-positive bac-
teria at low micromolar concentrations (see Table 1). Although RW-
BP100 is the most toxic analogue, it has the highest TI against the tested
Gram-negative bacteria. To decrease the toxic properties without
compromising the amphipathic character, shifting the position of the
Trp residuewithin the hydrophobic part of the amphipathic helix is a pos-
sibility [46].
AFM imaging suggests that BP100, R-BP100 and RW-BP100 exert
their action by targeting the anionic bacterial surface and disrupting
the membrane integrity. A mechanism dependent on electrostatic at-
tractions between the polycationic peptides and the anionic microbial
surface, followed by insertion into and permeabilization of the cytoplas-
mic membrane, is supported by biophysical results obtained with
Fig. 7. CD spectra of BP100 and its analogues in the absence or presence of lipid vesicles. CD
spectra of 50 μMof BP100 (A), R-BP100 (B) and RW-BP100 (C) in 10 mM phosphate buffer
containing 150 mM NaF or in the presence of POPC (500 μM) or in the presence of POPC/
POPG (1:1) (500 μM for R-BP100 and RW-BP100 and 1 mM for BP100). Insert in panel B
shows the top view of predicted helical three-dimensional structure of R-BP100 in anionic
membrane environment putting in evidence the amphipathic character of the helix. Hy-
drophilic amino acid residues are coloured in blue, hydrophobic amino acids are coloured
in green. The side chains of Phe and Tyr residues are represented by ball and stick. The
image was modulated using PyMOL Molecular Graphics System, version 1.2r3pre
(Schrödinger, LLC).
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tides in this study are able to bind and neutralize both LTA and LPS,
the negatively-charged molecules exposed at the Gram-negative and
Gram-positive bacteria, respectively. Furthermore, SPR and ﬂuores-
cence studies revealed that the peptides are able to bind and insert
into lipid bilayers, preferring anionic over neutral membranes. Upon in-
sertion into anionic membranes, the three peptides acquire an amphi-
pathic helical conformation (see Fig. 7B), insert into the lipid bilayer,
as conﬁrmed with the ﬂuorescence properties of the Tyr/Trp residue
(see Tables 3 and 4), and promote local perturbations, as revealed by
changes in the dipolar potential and vesicle aggregation (see Fig. 6).
The amphipathic helical conformation maximizes both electrostatic
and hydrophobic interactions with the membrane as the positive facepromotes binding to the anionic headgroups, whereas the nonpolar
face favours contact with the hydrophobic part of the membrane [47]
and allows insertion of the molecule into the hydrophobic core of the
lipid bilayer [11]. As a result of binding, insertion and accumulation
into the phospholipid bilayer, BP100 and its analogues induce mem-
brane disturbances that result in membrane permeabilization (see
Fig. 6D).
A mechanism of action dependent on binding to the anionic bacte-
rial surface, followed by peptide insertion into the membrane, and
permeabilization is in agreement with previous studies with BP100
[15,17]. Biophysical studies with model membranes and E. coli cells
revealed that BP100 binds to the anionic surface of E. coli cells, inserts
into the phospholipid bilayer and induces the leakage of cytoplasmic
content from E. coli cells [17].
Electrostatic interactions and amphipathic structure are clearly im-
portant for the activity of BP100, and its analogues, but they cannot ex-
plain the differences in the relative efﬁciency of the three peptides
against Gram-positive bacteria. All the tested peptides acquire a helical
amphipathic structure upon interaction with negatively-chargedmem-
branes, have identical ability to induce leakage fromnegatively-charged
membranes, have the same global net charge (+6) and are able to bind
to LTA, but BP100 has weak activity against Gram-positive bacteria,
whereas R-BP100 and RW-BP100 are active. The activity of the three an-
alogues against Gram-positive bacteria tracks with their membrane-
binding afﬁnity. Even with the same charge and preference for anionic
membranes, R-BP100 and RW-BP100, are better adapted to establish
interactions with membranes, than BP100. The preference of these
newly designed peptides for the membrane environment is in agree-
mentwith their higher overall hydrophobicity, butmight also be the re-
sult of particular features of the Arg and Trp residues.
The higher membrane-binding afﬁnity of R-BP100 over BP100 re-
sults from the substitution of the Lys residues with Arg. Although Lys
and Arg have the same charge, their membrane-binding properties are
different, suggesting that not only the charge but some speciﬁc proper-
ties of the guanidinium side chain in Arg are responsible for this behav-
iour [48]. One possible explanation is the pronounced ability of the
guanidinium group to establish strong bidentate H-bonds with phos-
phate moieties from two lipid headgroups, whereas the Lys ammonium
side chain can only interact with a single lipid headgroup (Fig. 8A & B)
[49]. In addition of beingbetter H-bonddonors, guanidiniumside chains
also establish stronger electrostatic cation–π interactions with aromatic
residues, than Lys residues [50]. Cation–π interactions occur between
basic residues (Arg and Lys) and aromatic residues (Phe, Tyr and Trp)
[50] and are important for peptide self-association within membranes
and facilitate deeper insertion into membranes by shielding cationic
side chains [50,51]. Furthermore, the Arg side chain is able to form
H-bonds even when involved in cation–π interactions, whereas the
Lys side chain cannot [52].
RW-BP100, besides having the Lys mutated with Arg, also possesses
a Trp instead of a Tyr residue, which confers higher afﬁnity and deeper
insertion into the membrane relative to the analogue R-BP100 (see
Fig. 6 and Table 4). These results are in agreementwith previous studies
showing that the Trp residue not only partitionsmore favourably in the
membrane interface, but is alsomore hydrophobic and has higher afﬁn-
ity for bulk hydrophobic phases, than Tyr [38]. In addition, the Trp res-
idue facilitates the insertion of the cationic Arg into the membrane
hydrophobic region through cation–π interactions [19] as above men-
tioned. The importance of Trp residues on the antimicrobial activity of
peptides has been previously correlated with their ability to bind to
lipid membranes [18,19,53] and is further supported in this study.
Based on our ﬁndings we propose that to efﬁciently kill Gram-
positive bacteria by a membrane-dependent mechanism a peptide
should be able to: target anionic membranes through electrostatic in-
teractions; partition into the water–lipid interface regions of mem-
branes through hydrophobic interactions and H-bonds; and be able to
more deeply insert into the hydrophobic membrane environment,
Fig. 8. Representation of the predicted helical three-dimensional structure of BP100 and its analogues in anionic membrane environment. (A) Side view of BP100 showing the ability of Lys
residues to establishmonodentate H-bonds. (B) Side view of RW-BP100 showing the ability of Arg residues to establish bidentate H-bondswith phosphate groups from two different phospho-
lipids. The colour scheme is the same as in Fig. 7B; the two images were modulated using PyMOL Molecular Graphics System, version 1.2r3pre (Schrödinger, LLC).
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tant to shield the charge of the cationic residues and disrupt the phos-
pholipid membrane.
The three peptides are highly active against the tested Gram-
negative bacteria, showing that these bacteria can be targeted and
disrupted by peptides containing either Arg or Lys residues.We propose
that to kill Gram-negative bacteria, H-bond formation and cation–π
interactions are not as important as for Gram-positive bacteria. The
Gram-negative bacterial surface is covered with LPS molecules, which
form a very compact and impermeable layer due to non-covalent
associations with divalent (calcium and magnesium) cations [54]; the
activity of cationic peptides against Gram-negative bacteria has been
correlated with their ability to bind and cross the LPS barrier by
displacing divalent cations from their binding sites [1,41,54] andeventu-
ally disrupting the cytoplasmic membrane. A mechanism of action de-
pendent on binding and crossing the LPS barrier before disrupting the
inner membrane is consistent with the E. coli strain CGSC 5167 (with
rough LPS, and therefore more penetrable) being more susceptible to
all the peptides, than the control strain ATCC 25922 (with smooth LPS)
(see Table 1). The importance of Arg and Trp residues for activity against
Gram-positive, but not Gram-negative bacteria, could be the result of a
larger peptidoglycan layer in the Gram-positive outer membrane, rela-
tive to Gram-negative bacteria, which requires the unique hydrogen
binding geometry of Arg and is facilitated by the complex amphipathic
properties of Trp that together promote stable and deep insertion into
the cell wall of Gram-positive bacteria.5. Conclusions
In this studywedesigned two BP100 analogues, which in addition to
being active against the tested Gram-negative were also active against
Gram-positive bacteria. Identiﬁcation of peptides with high activity
against Gram-negative andGram-positive bacteria is ofmajor relevance
due to the development of strains with resistance to common antibi-
otics. In fact, the novel peptides were here shown to be active against
several pathogenic bacteria, including strains with antibiotic resistance.Our studies revealed thatwhereas the antimicrobial activity of BP100
and its analogues against Gram-negative bacteria seems to bemainly de-
pendent on an ability to bind to LPS layer through electrostatic interac-
tions and membrane disruption through hydrophobic interactions. The
activity against Gram-positive, although dependent on electrostatic at-
tractions, and phospholipid membrane disruption, requires further
interactions with the cell wall components in which H-bonds and
cation–π interactions might play a role. Overall, the results obtained in
this study provide valuable information on the correlation between
amino acid sequence and antimicrobial activity that can guide the devel-
opment of new AMPs with either speciﬁc activity or a broader spectrum
of action.
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